CL2012003282A1 - Composicion farmaceutica topica que comprende, en base al peso total de la composicion a) 0,01 a 0,2% en peso de furoato de mometasona, b) 5 a 18% en peso de hexilenglicol, c) 20 a 40% en peso de agua y d) 25 a 70% en peso de una fase oleosa; y su uso para tratar o prevenir psoriasis, dermatitis atopica, entre otros. - Google Patents
Composicion farmaceutica topica que comprende, en base al peso total de la composicion a) 0,01 a 0,2% en peso de furoato de mometasona, b) 5 a 18% en peso de hexilenglicol, c) 20 a 40% en peso de agua y d) 25 a 70% en peso de una fase oleosa; y su uso para tratar o prevenir psoriasis, dermatitis atopica, entre otros.Info
- Publication number
- CL2012003282A1 CL2012003282A1 CL2012003282A CL2012003282A CL2012003282A1 CL 2012003282 A1 CL2012003282 A1 CL 2012003282A1 CL 2012003282 A CL2012003282 A CL 2012003282A CL 2012003282 A CL2012003282 A CL 2012003282A CL 2012003282 A1 CL2012003282 A1 CL 2012003282A1
- Authority
- CL
- Chile
- Prior art keywords
- weight
- composition
- treat
- oil phase
- water
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Composición farmacéutica tópica que comprende, en base al peso total de la composición A) 0,01 a 0,2 % en peso de furoato de mometasona, B) 5 a 18 % en peso de hexilenglicol, C) 20 a 40 % en peso de agua y D) 25 a 70 % en peso de una fase oleosa; y su uso para tratar o prevenir psoriasis, dermatitis atópica, entre otros.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10382146A EP2394653A1 (en) | 2010-05-26 | 2010-05-26 | Topical pharmaceutical compositions comprising mometasone furoate |
| US36505010P | 2010-07-16 | 2010-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2012003282A1 true CL2012003282A1 (es) | 2013-01-25 |
Family
ID=42797321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012003282A CL2012003282A1 (es) | 2010-05-26 | 2012-11-23 | Composicion farmaceutica topica que comprende, en base al peso total de la composicion a) 0,01 a 0,2% en peso de furoato de mometasona, b) 5 a 18% en peso de hexilenglicol, c) 20 a 40% en peso de agua y d) 25 a 70% en peso de una fase oleosa; y su uso para tratar o prevenir psoriasis, dermatitis atopica, entre otros. |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US20140200203A1 (es) |
| EP (2) | EP2394653A1 (es) |
| JP (1) | JP5743241B2 (es) |
| KR (1) | KR101790371B1 (es) |
| CN (1) | CN102883725B (es) |
| AR (1) | AR081765A1 (es) |
| AU (1) | AU2011257586B2 (es) |
| BR (1) | BR112012030006A2 (es) |
| CA (1) | CA2794553C (es) |
| CL (1) | CL2012003282A1 (es) |
| CO (1) | CO6640244A2 (es) |
| DK (1) | DK2575822T3 (es) |
| EA (1) | EA022967B1 (es) |
| ES (1) | ES2595250T3 (es) |
| HK (1) | HK1177893A1 (es) |
| HR (1) | HRP20161288T1 (es) |
| HU (1) | HUE029818T2 (es) |
| IL (1) | IL222163B (es) |
| LT (1) | LT2575822T (es) |
| ME (1) | ME02555B (es) |
| MX (1) | MX2012013642A (es) |
| MY (1) | MY160377A (es) |
| NZ (1) | NZ602730A (es) |
| PL (1) | PL2575822T3 (es) |
| PT (1) | PT2575822T (es) |
| RS (1) | RS55233B1 (es) |
| SG (2) | SG184405A1 (es) |
| SI (1) | SI2575822T1 (es) |
| SM (1) | SMT201600342B (es) |
| TW (1) | TWI473615B (es) |
| UY (1) | UY33404A (es) |
| WO (1) | WO2011147536A2 (es) |
| ZA (1) | ZA201208420B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2394653A1 (en) | 2010-05-26 | 2011-12-14 | Almirall, S.A. | Topical pharmaceutical compositions comprising mometasone furoate |
| WO2015005419A1 (ja) * | 2013-07-11 | 2015-01-15 | 株式会社ポーラファルマ | 使用時泡状を呈する外用組成物 |
| GB2540764A (en) * | 2015-07-24 | 2017-02-01 | Fontus Health Ltd | Topical composition |
| US11993571B2 (en) * | 2017-03-10 | 2024-05-28 | Rutgers, The State University Of New Jersey | Indole derivatives as efflux pump inhibitors |
| EP3492068A1 (en) * | 2017-12-01 | 2019-06-05 | NCP NewCare Products GmbH | Composition for treating onychomycosis |
| US20210322585A1 (en) * | 2020-04-21 | 2021-10-21 | Deloren E. Anderson | Silver titanium dioxide coating material, atomized silver titanium dioxide solution for inhaling and photocatalytic titanium dioxide solution for tattoo removal |
| CN114767630A (zh) * | 2022-06-06 | 2022-07-22 | 黑龙江中医药大学 | 一种治疗变应性鼻炎的药物组合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4808610A (en) | 1986-10-02 | 1989-02-28 | Schering Corporation | Mometasone furoate anti-inflammatory cream composition using hexylene glycol |
| US4775529A (en) | 1987-05-21 | 1988-10-04 | Schering Corporation | Steroid lotion |
| AU6974191A (en) | 1989-12-20 | 1991-07-18 | Schering Corporation | Stable cream and lotion bases for lipophilic drug compositions |
| JP3830963B2 (ja) | 1993-12-21 | 2006-10-11 | シェーリング コーポレイション | 乾癬治療 |
| US5696105A (en) * | 1996-03-14 | 1997-12-09 | Hackler; Walter A. | Antifungal nail composition |
| WO1999018971A1 (en) | 1997-10-09 | 1999-04-22 | Schering Corporation | Mometasone furoate suspensions for nebulization |
| TR200201343A2 (tr) | 2002-05-17 | 2003-12-22 | Orva İlaç Sanayi̇ Ve Ti̇caret A. Ş. | Kortikosteroid ve antiseptik içeren farmasötik bileşim |
| WO2004105686A2 (en) | 2003-05-23 | 2004-12-09 | Taro Pharmaceuticals U.S.A., Inc. | Novel topical steroid cream formulations |
| DE102006034883A1 (de) | 2006-07-25 | 2008-01-31 | Hermal Kurt Herrmann Gmbh & Co. Ohg | Pharmazeutische Zusammensetzung enthaltend Mometasonfuroat |
| EP2120868A4 (en) | 2007-04-11 | 2010-08-25 | Perrigo Israel Phamaceuticals | LOW-DOSED MOMETASON FORMULATIONS |
| EP2394653A1 (en) | 2010-05-26 | 2011-12-14 | Almirall, S.A. | Topical pharmaceutical compositions comprising mometasone furoate |
-
2010
- 2010-05-26 EP EP10382146A patent/EP2394653A1/en not_active Withdrawn
-
2011
- 2011-05-13 LT LTEP11719487.8T patent/LT2575822T/lt unknown
- 2011-05-13 MY MYPI2012004874A patent/MY160377A/en unknown
- 2011-05-13 PL PL11719487T patent/PL2575822T3/pl unknown
- 2011-05-13 SI SI201130986A patent/SI2575822T1/sl unknown
- 2011-05-13 DK DK11719487.8T patent/DK2575822T3/en active
- 2011-05-13 SG SG2012073235A patent/SG184405A1/en unknown
- 2011-05-13 ME MEP-2016-187A patent/ME02555B/me unknown
- 2011-05-13 NZ NZ602730A patent/NZ602730A/en not_active IP Right Cessation
- 2011-05-13 EP EP11719487.8A patent/EP2575822B1/en active Active
- 2011-05-13 WO PCT/EP2011/002369 patent/WO2011147536A2/en active Application Filing
- 2011-05-13 KR KR1020127029977A patent/KR101790371B1/ko active IP Right Grant
- 2011-05-13 AU AU2011257586A patent/AU2011257586B2/en not_active Ceased
- 2011-05-13 ES ES11719487.8T patent/ES2595250T3/es active Active
- 2011-05-13 SG SG10201502252YA patent/SG10201502252YA/en unknown
- 2011-05-13 HU HUE11719487A patent/HUE029818T2/en unknown
- 2011-05-13 CA CA2794553A patent/CA2794553C/en not_active Expired - Fee Related
- 2011-05-13 EA EA201291335A patent/EA022967B1/ru not_active IP Right Cessation
- 2011-05-13 PT PT117194878T patent/PT2575822T/pt unknown
- 2011-05-13 CN CN201180023073.7A patent/CN102883725B/zh active Active
- 2011-05-13 RS RS20160837A patent/RS55233B1/sr unknown
- 2011-05-13 MX MX2012013642A patent/MX2012013642A/es active IP Right Grant
- 2011-05-13 BR BR112012030006A patent/BR112012030006A2/pt not_active Application Discontinuation
- 2011-05-13 JP JP2013511568A patent/JP5743241B2/ja not_active Expired - Fee Related
- 2011-05-13 US US13/699,333 patent/US20140200203A1/en not_active Abandoned
- 2011-05-24 TW TW100118106A patent/TWI473615B/zh not_active IP Right Cessation
- 2011-05-24 UY UY0001033404A patent/UY33404A/es not_active Application Discontinuation
- 2011-05-24 AR ARP110101784A patent/AR081765A1/es unknown
-
2012
- 2012-09-27 IL IL222163A patent/IL222163B/en active IP Right Grant
- 2012-11-08 ZA ZA2012/08420A patent/ZA201208420B/en unknown
- 2012-11-23 CO CO12212409A patent/CO6640244A2/es not_active Application Discontinuation
- 2012-11-23 CL CL2012003282A patent/CL2012003282A1/es unknown
-
2013
- 2013-05-13 HK HK13105652.3A patent/HK1177893A1/zh not_active IP Right Cessation
-
2015
- 2015-10-15 US US14/883,898 patent/US9907807B2/en active Active
-
2016
- 2016-09-29 SM SM201600342T patent/SMT201600342B/it unknown
- 2016-10-06 HR HRP20161288TT patent/HRP20161288T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2012003282A1 (es) | Composicion farmaceutica topica que comprende, en base al peso total de la composicion a) 0,01 a 0,2% en peso de furoato de mometasona, b) 5 a 18% en peso de hexilenglicol, c) 20 a 40% en peso de agua y d) 25 a 70% en peso de una fase oleosa; y su uso para tratar o prevenir psoriasis, dermatitis atopica, entre otros. | |
| BR112015019657A2 (pt) | composições tópicas e métodos de uso das mesmas | |
| CR20150629A (es) | Compuestos químicos | |
| CL2013001589A1 (es) | Uso de una emulsion que comprende 0,08% en peso o menos de aceite esencial antimicrobiano, goma acacia y agua para proporcionar un efecto antimicrobiano en una composicion acuosa; proceso para mejorar el efecto antimicrobiano de un aceite esencial antimicrobiano; y composicion acuosa que comprende una emulsion antimicrobiana. | |
| UY33396A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| CR20140365A (es) | Compuestos de carbamato y preparación y uso de los mismos | |
| GT201400111A (es) | Triazolopiridinas sustituidas | |
| UY35040A (es) | Pirrolopirimidinilamino-benzotiazolonas sustituidas | |
| CL2013000675A1 (es) | Compuestos derivados de pirazolamida sustituidas, con actividad sobre pge2/ep4; composicion farmaceutica que los comprende; y su uso para el tratamiento de la esclerosis multiple y la artritis reumtoide. | |
| CL2014003081A1 (es) | Una composicion farmaceutica topica que comprende, en base al peso total de la composicion, 1,5-5 % en peso de terbinafina, 15-35 % en peso de urea y mas que 25 % en peso de agua; y su uso para el tratamiento topico de una infeccion fungica, preferiblemente onicomicosis. | |
| CL2011000214A1 (es) | Composicion farmaceutica que comprende progesterona micronizada y aceite de cartamo tipo ii; y uso para el tratamiento de una condicion relacionada con la insuficiencia de secrecion de progesterona. | |
| DOP2015000170A (es) | Compuestos químicos | |
| DOP2016000007A (es) | Pirazolpiridinas sustituidas | |
| SV2017005466A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| UY31922A (es) | Compuestos | |
| UY33530A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias | |
| BR112015020222A8 (pt) | composto de azetidiniloxifenilpirrolidina, seus usos, e composições farmacêuticas | |
| CL2011000722A1 (es) | Composicion farmaceutica en forma de unguento estable al almacenamiento, que comprende: a) un compuesto de vitamina d, b) un corticosteroide y c) un compuesto alquilamino sustituido, en un vehiculo de petrolato que opcionalmente contiene aceite mineral, tocoferol o una combinacion de ellos; uso en tratamiento de la psoriasis. | |
| AR084197A1 (es) | Composicion para uso topico para el tratamiento de trastornos de la piel | |
| BR112014029874A8 (pt) | composição farmacêutica do tipo emulsão óleo em água, composições e uso da composição farmacêutica | |
| BR112015001627A2 (pt) | composição farmacêutica, respectivos usos e método para diminuir a frequência de micção | |
| AR081017A1 (es) | Composicion topica y uso de la misma para la profilaxis y el tratamiento de los defectos relacionados con dermopatias inflamatorias | |
| CL2015001502A1 (es) | Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma. | |
| BR112015015857A2 (pt) | composição tópica e método de melhorar a microcirculação da pele | |
| AR097123A1 (es) | Composición espumable para el cuidado personal que comprende una fase oleosa continua y método de preparación |